Summit Therapeutics (MEX:SMMT) Buyback Yield %: 0.00 (As of Sep. 09, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:SMMT Summit Therapeutics Inc MEX:SMMT
30 GF Score
Price MXN290.12
! 2 Warning Signs
View Full Analysis

What is Summit Therapeutics Buyback Yield %?

Summit Therapeutics MEX:SMMT 30 Buyback Yield % is 0.00 as of Sep. 09, 2026. GuruFocus rates MEX:SMMT with a GF Score™ of 30/100. The stock has 2 warning signs investors should review. Among 697 Biotechnology companies, Summit Therapeutics ranks worse than 143471.88% on this metric.

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Summit Therapeutics's current buyback yield was 0.00%.

Summit Therapeutics Buyback Yield % Historical Data

* Premium members only.

The historical data trend for Summit Therapeutics's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Summit Therapeutics Buyback Yield % Chart

Summit Therapeutics Annual Data
Trend Jan16 Jan17 Jan18 Jan19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Buyback Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 -3.74 -3.90

Summit Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 -4.46 0.00 0.00

MEX:SMMT vs TECH, AXSM, KRYS: Buyback Yield % Comparison

For the Biotechnology subindustry, Summit Therapeutics's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Summit Therapeutics Buyback Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Summit Therapeutics's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Summit Therapeutics's Buyback Yield % falls into.


MEX:SMMT
30GF Score
Summit Therapeutics Inc MEX:SMMT
Buyback Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Summit Therapeutics Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Summit Therapeutics's Buyback Yield for the fiscal year that ended in Dec. 2025 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (0 + 10885.616) / 279133.56
=-3.90%

Summit Therapeutics's annualized Buyback Yield for the quarter that ended in Jun. 2026 is calculated as

Buyback Yield=Net Issuance of Stock(TTM) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) (TTM)** / Market Cap
=- (0 + 0) / 230099.9744
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .

Frequently Asked Questions Learn more about Buyback Yield % →
What does a Buyback Yield % of 0.00 mean?
Summit Therapeutics (MEX:SMMT) has a Buyback Yield % of 0.00 as of Sep. 09, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Summit Therapeutics and its competitors. According to the industry distribution chart, Summit Therapeutics ranks #999999 out of 697 companies in the Biotechnology industry.
Is Summit Therapeutics' Buyback Yield % too high?
Summit Therapeutics' current Buyback Yield % is 0.00. Based on the distribution chart, Summit Therapeutics ranks #999999 out of 697 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Summit Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Summit Therapeutics' Buyback Yield % compare to TECH and AXSM?
According to the Biotechnology industry distribution chart, Summit Therapeutics ranks #999999 out of 697 companies for Buyback Yield %. This places Summit Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Summit Therapeutics and its competitors. Summit Therapeutics's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Summit Therapeutics stock overvalued right now?
Summit Therapeutics (MEX:SMMT) has a current Buyback Yield % of 0.00. The current Buyback Yield % is 0.00. Summit Therapeutics' overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Summit Therapeutics (MEX:SMMT), the current Buyback Yield % is 0.00 as of Sep. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Summit Therapeutics Business Description

Other Exchanges SMMT:USA
Address 601 Brickell Key Drive, Suite 1000, Miami, FL, USA, 33131
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
30GF Score

Get the complete analysis for MEX:SMMT

Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN290.12
Price